BRCA1 and BRCA2 mutations in ovarian cancer: Covariation with specific cytogenetic features
Akash Koul(Norwegian Cancer Society), Mona Ridderheim(Lund University), Oskar T. Johannsson(Lapland Central Hospital), Roger Wïllén, Tanja Pejović(Oregon Health & Science University), Susanne Malander(Lund University), Niklas Loman(Lund University), Håkan Olsson(Nokia (Finland)), Sverre Heim(Oslo University Hospital)
Cited by 13
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
|Cancer Cell|2017|534